EVOLUS, INC. Payments to Acquire Investments
EVOLUS, INC. (EOLS) reported Payments to Acquire Investments of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2022-03-03
- EVOLUS, INC. payments to acquire investments for the quarter ending 2021-12-31 was $0.00.
- EVOLUS, INC. payments to acquire investments for the quarter ending 2021-09-30 was $0.00.
- EVOLUS, INC. payments to acquire investments for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- EVOLUS, INC. payments to acquire investments for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- EVOLUS, INC. payments to acquire investments for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- EVOLUS, INC. payments to acquire investments for fiscal 2020 was $74.67M, a 34.43% decline from fiscal 2019.
- EVOLUS, INC. payments to acquire investments for fiscal 2019 was $113.87M.
- EVOLUS, INC. payments to acquire investments for fiscal 2018 was $0.00.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 10-K · filed 2022-03-03 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 derived: sum of 2 quarters · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $0.00 derived: sum of 4 quarters · filed 2022-03-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $0.00 derived: sum of 3 quarters · filed 2022-03-03 | $24.98M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $0.00 derived: sum of 2 quarters · filed 2022-03-03 | $24.98M derived: sum of 3 quarters · filed 2022-03-03 | $74.67M 10-K · filed 2022-03-03 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $24.98M derived: sum of 2 quarters · filed 2021-11-02 | $74.67M 10-Q · filed 2021-11-02 | $89.55M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $24.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $74.67M 10-Q · filed 2021-08-04 | $89.55M derived: sum of 3 quarters · filed 2021-08-04 | $94.52M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $49.69M 10-Q · filed 2021-05-12 | $64.57M derived: sum of 2 quarters · filed 2021-05-12 | $69.54M derived: sum of 3 quarters · filed 2021-05-12 | $84.35M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $14.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $19.86M derived: sum of 2 quarters · filed 2021-03-25 | $34.66M derived: sum of 3 quarters · filed 2021-03-25 | $113.87M 10-K · filed 2021-03-25 |
| 2019-09-30 | $4.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $19.78M derived: sum of 2 quarters · filed 2020-10-29 | $98.98M 10-Q · filed 2020-10-29 | $98.98M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $14.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $94.01M 10-Q · filed 2020-08-10 | $94.01M derived: sum of 3 quarters · filed 2020-08-10 | $94.01M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $79.20M 10-Q · filed 2020-05-11 | $79.20M derived: sum of 2 quarters · filed 2020-05-11 | $79.20M derived: sum of 3 quarters · filed 2020-05-11 | $79.20M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $0.00 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $0.00 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |